Archford Capital Strategies LLC Buys Shares of 1,690 Medpace Holdings, Inc. $MEDP

Archford Capital Strategies LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,690 shares of the company’s stock, valued at approximately $949,000.

Other institutional investors also recently modified their holdings of the company. Cibc World Market Inc. acquired a new stake in shares of Medpace during the third quarter valued at about $5,033,000. Wealth Enhancement Advisory Services LLC grew its holdings in Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after acquiring an additional 9,117 shares during the last quarter. Brighton Jones LLC increased its position in Medpace by 160.4% in the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock valued at $2,087,000 after acquiring an additional 2,501 shares during the period. Baillie Gifford & Co. increased its position in Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after acquiring an additional 62,503 shares during the period. Finally, Capital Fund Management S.A. raised its stake in shares of Medpace by 129.5% during the third quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after acquiring an additional 18,287 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.30% of the company’s stock.

Medpace Stock Performance

Medpace stock opened at $489.48 on Thursday. The stock has a market capitalization of $13.89 billion, a price-to-earnings ratio of 31.99, a PEG ratio of 2.30 and a beta of 1.39. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The stock’s 50 day moving average price is $485.99 and its two-hundred day moving average price is $537.17.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.49. The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MEDP shares. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and cut their price target for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Truist Financial lowered their target price on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research report on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Medpace has an average rating of “Hold” and an average price target of $486.67.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.